CARLSBAD, Calif., June 10, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) announced today the introduction of Oncomine® Next Gen Sequencing Power Tools, an analytics offering that will allow cancer researchers to explore results from in-depth analysis of next generation sequencing (NGS) data, including data from The Cancer Genome Atlas. In total, more than 4,500 paired tumor and samples have been analyzed to date. "NGS has significant potential to deliver insights into what drives cancers and how the disease might be combated," said Dan Rhodes, Ph.D., head of medical science informatics for Life Technologies. "However, the field has only begun to take advantage of the enormous amounts of data becoming available. The Oncomine NGS Power Tools provide simple access to comprehensive findings, many of them novel, from a team with a proven track record of mining scientific value from big data." Oncomine® NGS Power Tools constitutes a suite of software tools that enable cancer researchers to easily survey novel predicted driver mutations and gene fusions across all cancers and within two dozen specific cancers types, as well as explore simple summary analyses that integrate multiple types of gene and pathway aberrations with clinical data. In addition to basic research applications, the NGS tools also provide a foundation for specialized biomarker services to pharma and biotech customers in their efforts to evaluate NGS data for biomarker and companion diagnostic development. With collaborators from the University of Michigan Medical School, Life Technologies scientists used the NGS Power Tools to discover FGFR gene fusions across a range of cancer types. These results are reported in the current issue of Cancer Discovery. The investigators discovered FGFR fusions across a highly diverse set of nine distinct tumor types, including lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell cancer. Normal cell lines transfected with fusion constructs exhibited enhanced growth that was sensitive to FGFR inhibitors, indicating that the fusion genes were in fact acting to drive the cancers.